Analysts have been eager to weigh in on the Healthcare sector with new ratings on TCR2 Therapeutics (TCRR – Research Report) and Nurix Therapeutics (NRIX – Research Report).
TCR2 Therapeutics (TCRR)
Jefferies analyst Kelly Shi downgraded TCR2 Therapeutics to Hold today and set a price target of $3.00. The company’s shares closed last Wednesday at $1.55.
According to TipRanks.com, Shi is ranked 0 out of 5 stars with an average return of
TCR2 Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.67, implying a 311.7% upside from current levels. In a report issued on March 7, H.C. Wainwright also downgraded the stock to Hold.
See the top stocks recommended by analysts >>
Nurix Therapeutics (NRIX)
According to TipRanks.com, Lawson is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nurix Therapeutics with a $31.50 average price target, implying a 245.8% upside from current levels. In a report issued on February 27, Oppenheimer also initiated coverage with a Buy rating on the stock with a $25.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TCRR:
- TCR2 Therapeutics downgraded to Hold from Buy at Truist
- TCR2 Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Adaptimmune downgraded to Hold from Buy at JonesResearch
- Adaptimmune Craters after Acquiring TCRR
- Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
